// App-Quantinova.ai

: Ocriplasmin in the treatment of vitreomacular traction – against

Researchers

Presenter

  • H. Zambarakji

Principal Investigators

  • N/A

Medical Centers

  • Ophthalmology Department, Eye Treatment Centre, Barts Health Whipps Cross University Hospital NHS Trust, London, United Kingdom

Locations

  • United Kingdom

Companies

  • N/A

Study Components

Therapeutic Area

  • Ophthalmology (OP)

  • Genetic Disorder

Disease

  • Rhegmatogenous retinal detachment autosomal dominant

Biomarkers

  • ETS transcription factor ERG

Drug/Treatment

  • Ocriplasmin

Outcome

  • N/A

Study Design

  • Placebo Control

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved